These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 111446)

  • 1. Suppression of the TSH response to TRH by thyroxine therapy in differentiated thyroid carcinoma patients.
    Lamberg BA; Rantanen M; Saarinen P; Liewendahl K; Sivula A
    Acta Endocrinol (Copenh); 1979 Jun; 91(2):248-56. PubMed ID: 111446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free thyroxine, free triiodothyronine, and thyrotropin concentrations in hypothyroid and thyroid carcinoma patients receiving thyroxine therapy.
    Liewendahl K; Helenius T; Lamberg BA; Mähönen H; Wägar G
    Acta Endocrinol (Copenh); 1987 Nov; 116(3):418-24. PubMed ID: 3687325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum thyrotropin and prolactin in the syndrome of generalized resistance to thyroid hormone: responses to thyrotropin-releasing hormone stimulation and short term triiodothyronine suppression.
    Sarne DH; Sobieszczyk S; Ain KB; Refetoff S
    J Clin Endocrinol Metab; 1990 May; 70(5):1305-11. PubMed ID: 2110573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of the optimal thyroxine dose with the TRH test for replacement and suppression therapy].
    Erne P; Staub JJ; Althaus B; Fleig Y; Girard J
    Schweiz Med Wochenschr; 1983 Dec; 113(50):1922-3. PubMed ID: 6420884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to thyrotropin releasing hormone: an objective criterion for the adequacy of thyrotropin suppression therapy.
    Hoffman DP; Surks MI; Oppenheimer JH; Weitzman ED
    J Clin Endocrinol Metab; 1977 May; 44(5):892-901. PubMed ID: 404309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The thyrotrophin response to thyrotrophin releasing hormone during treatment in patients with Graves' disease.
    Haug E; Frey HM; Sand T
    Acta Endocrinol (Copenh); 1977 Jun; 85(2):335-44. PubMed ID: 405834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TSH levels and TSH response to TRH as a guide to the replacement treatment of patients with thyroid carcinoma.
    Busnardo B; Vagelista R; Girelli ME; Bui F; Lazzi C
    J Clin Endocrinol Metab; 1976 May; 42(5):901-6. PubMed ID: 818103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly sensitive determination of TSH in the follow-up of TSH-suppressive therapy of patients with differentiated thyroid cancer.
    Mann K; Saller B; Mehl U; Hörmann R; Moser E
    Nuklearmedizin; 1988 Feb; 27(1):24-8. PubMed ID: 3368333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid vascular conductance: differential effects of elevated plasma thyrotropin (TSH) induced by treatment with thioamides or TSH-releasing hormone.
    Connors JM; Huffman LJ; Michalkiewicz M; Chang BS; Dey RD; Hedge GA
    Endocrinology; 1991 Jul; 129(1):117-25. PubMed ID: 1905224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of TSH-suppressive levothyroxine treatment in thyroid cancer patients: TRH testing versus basal TSH determination by a third generation assay.
    Görges R; Saller B; Eising EG; Quadbeck B; Mann K; Bockisch A
    Exp Clin Endocrinol Diabetes; 2002 Oct; 110(7):355-60. PubMed ID: 12397535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients.
    Bartalena L; Martino E; Pacchiarotti A; Grasso L; Aghini-Lombardi F; Buratti L; Bambini G; Breccia M; Pinchera A
    J Clin Endocrinol Metab; 1987 Apr; 64(4):849-55. PubMed ID: 3818906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the nocturnal serum thyrotropin (TSH) surge, as assessed by TSH ultrasensitive assay, in patients receiving long term L-thyroxine suppression therapy and in patients with various thyroid disorders.
    Bartalena L; Martino E; Falcone M; Buratti L; Grasso L; Mammoli C; Pacchiarotti A; Aghini-Lombardi F; Balzano S; Pinchera A
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1265-71. PubMed ID: 3680483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSH suppression by octreotide in differentiated thyroid carcinoma.
    Maini CL; Sciuto R; Tofani A
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):335-9. PubMed ID: 8187297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained rises in serum thyrotropin, thyroxine, and triiodothyronine during long term, continuous thyrotropin-releasing hormone treatment in patients with amyotrophic lateral sclerosis.
    Kaplan MM; Taft JA; Reichlin S; Munsat TL
    J Clin Endocrinol Metab; 1986 Oct; 63(4):808-14. PubMed ID: 3091628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of an optimal saturation regimen with thyroxine or triiodothyronine.
    Busnardo B; Bui F; Girelli ME
    J Endocrinol Invest; 1983 Dec; 6(6):455-61. PubMed ID: 6423722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyrotropin secretion in thyrotoxic and thyroxine-treated patients: assessment by a sensitive immunoenzymometric assay.
    Spencer CA; Lai-Rosenfeld AO; Guttler RB; LoPresti J; Marcus AO; Nimalasuriya A; Eigen A; Doss RC; Green BJ; Nicoloff JT
    J Clin Endocrinol Metab; 1986 Aug; 63(2):349-55. PubMed ID: 3088021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
    Francia G; Davì MV; Petroziello A; Sussi PL
    Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repetitive administration of thyrotropin-releasing hormone results in small elevations of serum thyroid hormones and in marked inhibition of thyrotropin response.
    Snyder PJ; Utiger RD
    J Clin Invest; 1973 Sep; 52(9):2305-12. PubMed ID: 4199417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-related change in pituitary threshold for TSH release during thyroxine replacement therapy for cretinism.
    Sato T; Suzuki Y; Taketani T; Ishiguro K; Nakajima H
    J Clin Endocrinol Metab; 1977 Mar; 44(3):553-9. PubMed ID: 402383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.